Delcath Systems (NASDAQ:DCTH) Stock Price Up 1.6%

Delcath Systems, Inc. (NASDAQ:DCTH)’s share price rose 1.6% during mid-day trading on Tuesday . The company traded as high as $5.72 and last traded at $5.60. Approximately 220,934 shares were traded during trading, a decline of 2% from the average daily volume of 225,808 shares. The stock had previously closed at $5.51.

Analysts Set New Price Targets

DCTH has been the topic of a number of analyst reports. StockNews.com upgraded shares of Delcath Systems to a “sell” rating in a research note on Wednesday, March 27th. HC Wainwright increased their target price on shares of Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, Delcath Systems has a consensus rating of “Moderate Buy” and an average price target of $18.50.

Delcath Systems Price Performance

The stock has a market cap of $133.81 million, a P/E ratio of -1.77 and a beta of 0.53. The business’s fifty day moving average price is $4.54 and its 200 day moving average price is $3.96.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Tuesday, March 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.19. The business had revenue of $0.54 million during the quarter, compared to analyst estimates of $0.48 million. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 563.60%. During the same quarter last year, the business earned ($0.86) EPS. On average, analysts predict that Delcath Systems, Inc. will post -1.45 earnings per share for the current fiscal year.

Insider Activity at Delcath Systems

In other Delcath Systems news, Director Gil Aharon acquired 26,882 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was acquired at an average price of $3.72 per share, for a total transaction of $100,001.04. Following the acquisition, the director now directly owns 1,069,710 shares in the company, valued at $3,979,321.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 17.94% of the stock is owned by company insiders.

Institutional Trading of Delcath Systems

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Levin Capital Strategies L.P. increased its position in Delcath Systems by 22.5% during the 4th quarter. Levin Capital Strategies L.P. now owns 49,000 shares of the company’s stock valued at $204,000 after purchasing an additional 9,000 shares during the period. WealthPlan Investment Management LLC acquired a new stake in Delcath Systems during the 4th quarter valued at approximately $73,000. Armistice Capital LLC acquired a new stake in shares of Delcath Systems during the 3rd quarter worth approximately $664,000. ADAR1 Capital Management LLC acquired a new stake in shares of Delcath Systems during the 4th quarter worth approximately $962,000. Finally, Worth Venture Partners LLC acquired a new stake in shares of Delcath Systems during the 4th quarter worth approximately $1,224,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.